Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011

Figure 2

Change in volumes of individual antiparkinsonian agents by drug group. (a) Levodopa (L-dopa), (b) catechol-o-methyl transferase inhibitors (COMTI), (c) Amantadine, (d) dopamine agonists, (e) selegiline, and (f) anticholinergics. DDD defined daily dose.

(a)

(b)

(c)

(d)

(e)

(f)